Impairment of the Ability of HDL From Patients With Metabolic Syndrome but Without Diabetes Mellitus to Activate eNOS: Correction by S1P Enrichment.

Date publication

mars 2017

Journal

Arteriosclerosis, thrombosis, and vascular biology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DUVILLARD Laurence , Pr PETIT Jean-Michel , Pr VERGES Bruno , Mr MONIER Serge , Dr PAIS DE BARROS Jean-Paul

Tous les auteurs :
Denimal D, Monier S, Brindisi MC, Petit JM, Bouillet B, Nguyen A, Demizieux L, Simoneau I, Pais de Barros JP, Vergès B, Duvillard L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28360087

Résumé

High-density lipoprotein (HDL) from nondiabetic patients with metabolic syndrome (MetS) displays abnormalities in their lipidome, such as triglyceride enrichment and sphingosine-1-phosphate depletion. We hypothesized that these abnormalities could impair the ability of HDL to stimulate endothelial nitric oxide synthase (eNOS).

Mots clés

HDL, eNOS, metabolic syndrome, sphingosine

Référence

Arterioscler. Thromb. Vasc. Biol.. 2017 Mar;: